ReviewClinical microbiology reviews2007
Fusarium infections in immunocompromised patients.
Review in Clinical microbiology reviews, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 361 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
361 citing papers in PubMed, 4 syntheses or guidelines pooled it, 953 citations in OpenAlex.
- Restoring nature with microbes: bioremediation in the world's biodiversity hotspots.Applied and environmental microbiology · 2025Pooled it
- Fusarium species,Scedosporium species, and Lomentospora prolificans: A systematic review to inform the World Health Organization priority list of fungal pathogens.Medical mycology · 2024Pooled it
- Evolutionary trends in antifungal resistance: a meta-analysis.Microbiology spectrum · 2024Pooled it
- Performance of the beta-glucan test for the diagnosis of invasive fusariosis and scedosporiosis: a meta-analysis.Medical mycology · 2023Pooled it
- Impacts of climate extremes on plant pathogens, microbiomes and plant health.Nature reviews. Microbiology · 2026Review
- Development of a Gold Nanoparticle-Assisted Multiplex Polymerase Chain Reaction Assay for Selected Hospital-Acquired Infections-Associated Bacterial and Fungal Pathogens.ChemistryOpen · 2026Article
- Therapeutic Failure in Invasive Fungal Infections: Beyond Antifungal Resistance-A Narrative Review.Journal of fungi (Basel, Switzerland) · 2026Review
- RPA-CRISPR/Cas12a-Mediated Isothermal Amplification Technology for Visual Detection ofPlants (Basel, Switzerland) · 2026Article
- Dysbiosis of oral bacteriome and mycobiome associated with the severity of heart failure.BMC oral health · 2026Article
- Empowering fungal infection research with single-cell RNA sequencing.Communications biology · 2026Review
- Differential Thigmotropic Capacities Among Fusarial Isolates:Journal of fungi (Basel, Switzerland) · 2026Article
- Invasive Fusariosis: A Retrospective Case Series Evaluating In Vitro Minimum Inhibitory Concentrations and Clinical Response.Open forum infectious diseases · 2026Article
- Human Contact Frequency as a Dominant Ecological Driver of Fungal Community Assembly and Homogenization in Public Built Environments.Journal of microbiology and biotechnology · 2026Article
- Article
- The Multifaceted Menace ofBiology · 2026Review
- Invasive Fusariosis Among Patients with Acute Leukemia: A 12-Year Single-Center Experience in a Middle-Income Country.Mycopathologia · 2026Article
- Regulation of ABC Transporters and Ergosterol Biosynthesis by the Transcription Factor FvADS-1 Controls Azole Resistance and Virulence inJournal of fungi (Basel, Switzerland) · 2026Article
- Assessment of the molecular identification algorithm and its impact on antifungal susceptibilities against clinicalJAC-antimicrobial resistance · 2026Article
- Article
- Facultative heterochromatin mediated by core and accessory chromosome-encoded H3K27-specific methyltransferases controls virulence in a fungal phytopathogen.Nucleic acids research · 2026Article
301 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Fusarium species cause a broad spectrum of infections in humans, including superficial, locally invasive, and disseminated infections. The clinical form of fusariosis depends largely on the immune status of the host and the portal of entry, with superficial and localized disease occurring mostly in immunocompetent patients and invasive and disseminated disease affecting immunocompromised patients. Risk factors for severe fusariosis include prolonged neutropenia and T-cell immunodeficiency, especially in hematopoietic stem cell transplant recipients with severe graft-versus-host disease. The most frequent presentation of disseminated fusariosis is a combination of characteristic cutaneous lesions and positive blood cultures, with or without lung or sinus involvement. The prognosis is poor and is determined largely by degree of immunosuppression and extent of infection, with virtually a 100% death rate among persistently neutropenic patients with disseminated disease. These infections may be clinically suspected on the basis of a constellation of clinical and laboratory findings, which should lead to prompt therapy. Treatment options include the lipid formulations of amphotericin B, voriconazole, and posaconazole. Prevention of fusarial infection among high-risk patients should be considered.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.